279.52 0.00 (0.00%)
After hours: 5:38PM EDT
|Bid||278.00 x 800|
|Ask||279.50 x 800|
|Day's Range||274.08 - 280.46|
|52 Week Range||165.23 - 306.08|
|Beta (5Y Monthly)||0.94|
|PE Ratio (TTM)||35.28|
|Earnings Date||Oct 28, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||305.57|
People across the world increased their online buying during the coronavirus-related lockdowns. As the largest e-commerce retailer in the world, Amazon was a prime beneficiary. The convenience of shopping online, combined with continued worries about COVID-19, should keep Amazon's sales momentum going even if the recession continues for a much longer period.
Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.
Futures rose Friday, signaling further gains for the coronavirus stock market rally on Apple, Amazon, Facebook and Google earnings.
Vertex Pharmaceuticals (NASDAQ: VRTX) has been on a roll so far in 2020. The company announced its second-quarter results after the market closed on Thursday. It looks like Vertex's good times will keep rolling.
Vertex (VRTX) delivered earnings and revenue surprises of 22.54% and 8.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2020 and revised upward its full-year 2020 financial guidance for total cystic fibrosis (CF) product revenues.
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Successful treatments would demonstrate the potential for gene therapy—and boost a number of biotech companies.
IBD 50 and Sector Leaders member Vertex Pharmaceuticals (VRTX) is expected to report earnings on Jul. 30. It's trading now trading 6% below the 295.65 buy point from a second-stage flat base that it cleared earlier. Understand that buying a stock just before it reports is risky, since an EPS or sales miss could send it sharply lower. You can...
On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $291.23, marking a -0.06% move from the previous day.
While the Dow Jones Industrial Average finished up 0.6%, the Nasdaq cut its early mild losses to close ahead 0.2%.
The Dow Jones Industrial Average rallied 300 points early Tuesday after the European Union agreed to a coronavirus stimulus fund.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of a global Phase 3 study of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis (CF) ages 12 years and older who have one copy of the F508del mutation and one gating mutation (F/G) or one copy of the F508del mutation and one residual function mutation (F/RF). The study met its primary endpoint of mean absolute within-group change in percent predicted forced expiratory volume in 1 second (ppFEV1) from baseline through 8 weeks of treatment, demonstrating a statistically significant 3.7 percentage point (p<0.0001) improvement in ppFEV1 in patients treated with TRIKAFTA compared to their baseline after a 4-week run-in of treatment on ivacaftor or tezacaftor/ivacaftor. The study met all secondary endpoints, including a statistically significant mean within-group reduction of 22.3 mmol/L from baseline in sweat chloride (p<0.0001). The regimen was generally well-tolerated, and safety data were consistent with those observed in previous Phase 3 studies with TRIKAFTA.
Vertex is up more than 30% year to date, while Regeneron's shares have skyrocketed close to 70%. It's easy to see why investors like Vertex and Regeneron. The company's biggest winner is its newest product, Trikafta.
TRIA, a principal-led architecture firm with a focus on designing unique workspaces for science, technology, and corporate clients, announced today that it is designing a new cell and genetic therapies research site in the Boston area for Vertex Pharmaceuticals, Inc. (Nasdaq: VRTX), a global biotechnology company. The Vertex Cell and Genetic Therapies site will house the company's research, development, and clinical manufacturing activities for cell and genetic therapies - two rapidly emerging therapeutic modalities with the potential to treat—and even cure—several of the diseases Vertex is focused on. TRIA was selected to provide architectural services for the design and build-out of laboratory, office, and amenity spaces for Vertex's newly constructed 268,000 SF research site.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2020 financial results on Thursday, July 30, 2020 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).
To lead a pharmaceutical company, or invest in one, you need vision and fortitude. Jeffrey Leiden, executive chairman and former Vertex CEO, has both.